Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger

OrchidPharm~~ -- A Dhanuka Group Company ------------------------------------ August 14, 2026 National Stock Exchange of India Limited, SSE Limited Fxrhnnop Pln7n, Rnnrlrn I<l.Irla Complex, Phiroze Jeejeebhoy Towen., DQIQI Sandra (E), Mumbai-400051 Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Outcome of Board Meeting - Orchid Pharma Limited ("the Company") Dear Sir/Madam, With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of Schedule III and Regulation 33 of Securities and Exchange Soard of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 and in continuation to the prior intimation given by the Company on August 11, 2026 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. August 14, 2026 (commenced at 14:00 P.M.(IST) and concluded at 18: 15 P.M. (1ST) has inter-alia considered and approved the below mentioned matters: - Revised Audited Standalone & Consolidated Financial Results of the Company for quarter and financial year ended on March 31, 2026 along with the revised statement of assets & liabilities, revised cash flow statement and revised auditors' reports issued by M/s. Singhi & Co., Statutory Auditors of the Company on account of sanctioned scheme of amalgamation & arrangement of Dhanuka laboratories limited (amalgamating company) with Orchid Pharma limited (amalgamated company) and their respective shareholders and creditors by Hon'ble National Company Law Tribunal, Chennai, being come into effect from July 10, 2026 with appointed date from April 01, 2024. Statement of impact of audit qualifications in respect of revised auditors' report with modified opinion on revised consolidated financial results and declaration in respect of auditors' report with unmodified opinion on revised standalone financial results of the company You are requested to take the above intimations on record. Encl. as above +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. Orchid Pharma Limited Regd. Office: Plot Nos. 121 -128, 128A -133, 138 -151,159 -164, SIDCO Industrial Estate, Alathur, Chengalpallu District -603110, Tamil Nadu, India Ph. +91 -44 -2744 4471 -78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com CIN : L24222TN1992PLC022994 Revised Statement of Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31,2026 (All amounts are in lakhs of Indian Rupees, unless otherwise stated) S, No, Particulars Revised Standalone financial resuHs (Refer Note 7) Revised Consolidated Financial Results (Refer Note 7) For the quarter ended For the year ended For the quarter ended For the year ended MI,ch 3~, 2028 Dec 31, 2025 March 31, 2025 MIlCh 31, 2028 March 31, 2025 Mllllh31,2028 Dec 31, 2025 March 31, 2025 M.Rlh 31, 2028 March 31, 2025 (Audltld) (Unaudited) (Audited) (Audited) (Audited) (Audllld) (Unaudited) (Audited) (Audited) (Audited) (Rell, Note 8) (Refer Note 6) (Rell, Not, 8) (Refer Note 6) Income from Operations 1 Net Sales !Income from operations 36,832.71 30,280.69 35,737.27 1,23,277.84 1,39,761.17 36,832.71 30,280.69 35,737.27 1,23,277.84 1,39,761.17 2 Other Income 1,372.81 1,041.69 725.78 5,648.69 3,643.18 777.37 543.63 489.82 3,641.83 3,197.74 3 Total Income (1+2) 38,205,52 31,322.38 36,463,05 1,28,926,53 1,43,404,35 37,610,08 30,824.32 36,227.09 1,26,919,67 1,42,958,91 4 Expenses Cost of materials consumed 20,983.93 18,580.42 21,207.93 77,139.16 91,268.65 20,983.93 18,580.42 21,207.93 77139.16 91,268.65 Changes in inventories of raw material. work-in-progress, stock-in-trade and 3,512.34 2,256.62 1,611.01 7,138.39 (2,194.50) 3,512.34 2,256.62 1,611.01 7138.39 (2,194.50) finished goods Purchases of Stock in trade 47.59 25.00 124.40 168.72 261.31 47.59 25.00 124.40 168.72 261.31 Employee benefit expenses 2,633.08 2,937.27 2,814.78 11,432.05 10,922.61 2,761.75 3,061.64 2,814.78 11765.46 10,922.61 Finance costs 194.97 215.89 350.75 896.15 1,278.82 196.39 216.75 344.29 898.43 1,278.82 Depreciation and amortization expense 1,118.44 1,093.45 1,062.91 4,335.60 4,190.93 1,090.31 1,099.60 1,073.87 4324.63 4,201.89 Other expenses 6,426.86 5,757.01 6,300.14 23,621.17 24,431.96 6,511.15 5,759.78 6,935.14 23708.71 25,067.42 Totat Expenses 34,917,21 30,865.66 33,471,92 1,24,731,24 1,30,159.78 35,103.46 30,999.81 34,111.42 1,25,143.50 1,30,806.20 5 Profit I (Loss) before exceptional items and tax (3·4) 3,288,31 456,72 2,991.13 4,195,29 13,244,57 2,506,62 (175,49) 2,115.67 1,776,17 12,152,71 6 Exceptional items (refer Note no.3) (22.02) (711.27) (733.29) (22.02) (711.27) (733.29) 7 Profit I (Loss) before tax (5+6) 3,266,29 (254.55) 2,991,13 3,462,00 13,244,57 2,484,60 (886,76) 2,115,67 1,042,88 12,152,71 8 Tax expense Currenttax Tax adjustments of earlier years 23.39 6.18 14.16 Deferred tax (968.53) (968.53) 0.17 (4.50) (978.65) (19.16) (978.65) Total Tax Expenses (968.53) (945.14) 0.17 (4.50) (972.47) (19.16) (964.49) 9 Profit I (Loss) for the period before share of profit of Associates (7·8) 3,266,29 (254.55) 3,959,66 3,462.00 14,189,71 2,484,43 (882,26) 3,088,14 1,062,04 13,117,20 q~AR-1i. , ~ 0 .. ij.:O - c.i" Orchid Pharma Limited Revised Statement 01 Audited Standalone and Consolidated Financial Results lor the quarter and year ended March 31, 2026 (Contd ... ) S.No. Particulars Revised Standalone linancial results Revised Consolidated Rinancial Results For the quarter ended For the For the quarter ended Forthe year ended year ended March 31, 2026 Dec 31, 2025 March 31, 2025 March 31, 2026 March 31, 2025 March 31, 2026 Dec 31, 2025 March 31, 2025 March 31, 2026 March 31, 2025 (Audited) (Unaudited) (Audited) (Audited) (Audited) (Audited) (Unaudiled) (Audiled) (Audited) (Audiled) (Reier Note 6 ) (Reier Nole 6) (Reier Nole 6 ) (Reier Nole 6) 10 Profit I (loss) for the period before share of profit of Associates 3,266.29 (254.55) 3,959.66 3,462.00 14,189.71 2,484.43 (882.26) 3,088.14 1,062.04 13,117.20 11 Add: Share 01 Prolitl (Loss) 01 Associales 99.51 (46.71) 316.11 (66.13) 389.85 12 Prolill (Loss) lor Ihe period (10+11) 3,266.29 (254.55) 3,959.66 3,462.00 14,189.71 2,583.94 (928.97) 3,404.25 995.91 13,507.05 13 Olher comprehensive income, nel 01 income lax a) (i) items that will not be reclassified to profit or loss 130.27 56.42 166.75 131.76 (75. f3) 130.27 56.42 166.75 131.76 (75.13) (ii) income tax relating to items that will not be reclassified to profit or loss b) (i) items that will be reclassified to profit or loss (ii) income tax relating to items that will be reclassified to profit or loss Tolal olher comprehensive incomel (loss), nel 01 income lax 130.27 56.42 166.75 131.76 (75.13) 130.27 56.42 166.75 131.76 (75.13) 14 Tolaf comprehensive incomel (Loss) lor Ihe period (12+13) 3,396.56 (198.13) 4,126.41 3,593.76 14,114.58 2,714.21 (872.55) 3,571.00 1,127.67 13,431.92 15 Paid-up equity share capital 5,988.52 5,988.52 5,988.52 5,988.52 5,988.52 5.988.52 5,988.52 5,988.52 5,988.52 5,988.52 (Including Shares pending allotment on account of Merger) Other Equity 1,58,679.07 1,55.085.30 1,50.442.18 1.49.404.67 Face value per share (Rs) 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 16 Earnings per equity share ': -Basic ( Rs.) 5.45 (0.43) 6.61 5.78 23.69 4.31 (1.55) 5.68 1.66 22.55 -Diluted (Rs.) 5.45 (0.43) 6.61 5.78 23-.69 - 4.31 (1.55) 5.68 1.66 22.55 , , EPS for the quarters are not [Showing first 8,000 characters — download PDF for full document]